Trial Profile
A study evaluating lenalidomide as a first line therapy followed by hypomethylating agents as second line therapy and vice versa in non-del5q lower-risk myelodysplastic syndrome patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jan 2017
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 20 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology